bendamustine hydrochloride has been researched along with carboplatin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fischer, JR; Heider, A; Koch, JA; Köster, W; Niederle, N; Stahl, M; Stamatis, G; Wilke, H | 1 |
| Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP | 1 |
| Do, YR; Hong, JY; Hyun, SY; Jo, JC; Kim, JA; Kim, MK; Kim, WS; Koh, YI; Lee, SS; Lee, WS; Oh, YH; Park, BB; Suh, C; Won, JH; Yang, DH | 1 |
| Alpdogan, SO; Carabasi, M; Chapman, A; DiMeglio, M; Filicko-OHara, J; Flomenberg, N; Gaballa, S; Ghimire, S; Gong, J; Martinez-Outschoorn, U; Pan, J; Porcu, P; Pro, B; Ramirez, M; Rose, L; Wagner, JL; Weiss, M | 1 |
4 trial(s) available for bendamustine hydrochloride and carboplatin
| Article | Year |
|---|---|
Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Patient Selection; Probability; Risk Assessment | 2007 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss | 2015 |
A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carboplatin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Progression-Free Survival; Salvage Therapy; Thrombocytopenia; Young Adult | 2019 |
Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Carboplatin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy | 2021 |